PHASE Scientific Americas Secures $35M Series C Funding to Launch INDICAID Health: Empowering At-Home Diagnostics

PHASE Scientific Americas is thrilled to announce the successful culmination of our latest funding round, having raised $35,000,000 to further revolutionize the landscape of personal health care.

As a high-growth biotech startup founded by bioengineering scientists from UCLA, our core mission is to empower individuals by providing superior tools that offer better insights into their health.

This significant investment will be channeled into the enhancement and scaling of our flagship product, INDICAID health, a groundbreaking at-home testing solution designed to deliver fast, accurate, and accessible health assessments.

With INDICAID health, users benefit from a seamless integration of self-administered tests and the support of our CLIA-certified and CAP-accredited PHASE Lab, ensuring reliable sample processing and swift access to virtual care.

The funding will also enable us to expand our research and development efforts, strengthen our strategic partnerships, and broaden our reach to communities in need of high-quality health solutions.

We remain committed to our foundational values: being science driven, cultivating strong relationships, embracing straightforward communication, and ultimately being built to help you succeed.

The infusion of capital is not just an affirmation of the trust our investors place in us, but also a strong vote of confidence in the transformative potential of our technology.

As we expand our capabilities and explore new avenues to support personal health management, our commitment to innovation and excellence continues to drive us forward in our mission to empower every individual with the knowledge and tools for better health outcomes.